Search Results
Jun 02, 2026, 20:00 ET 2026 ASCO | 科倫博泰創新B7-H3 ADC SKB500首次人體研究數據公布
2026年6月3日 /美通社/ -- 2026年6月3日，四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)宣布，在美國芝加哥舉行的2026年美國臨床腫瘤學會(ASCO)年會上，吉林省腫瘤醫院劉海峰教授以快速口頭報告的形式公布了創新B7-H3 ADC SKB500治療晚期實體瘤的首次人體研究結果(摘要編號#3011 |分子靶向藥物與腫瘤生物學)。SKB500采用了高親和力、高親水性及內吞作用更強的抗體，並在抗體恆定區進行了沉默Fc效應功能的工程改造。此外，其抗體通過可裂解的親水性AAA連接子與具有中等毒性的載荷連接，藥物抗體比(
More news about: 科倫博泰
Jun 02, 2026, 11:32 ET MT Group Surpasses 5,000 Customized Biospecimen Collections, Reinforcing Its Position as a Leading Specialty CRO for Prospective Human Tissue and Blood Procurement
validating early-detection assays, baseline biomarker discovery programs, and pre-treatment cohorts in immuno-oncology and antibody-drug conjugate (ADC) target validation. Pathologist-reviewed quality control includes tumor content estimation, necrosis assessment, fixative confirmation, and morphology
More news about: MT Group
Jun 02, 2026, 10:05 ET CREATV BIO AND NEOVIA ONCOLOGY ANNOUNCE STRATEGIC PARTNERSHIP TO STUDY MULTIPLE DRUG RESISTANCE (MDR) IN SOLID TUMORS
therapy, Neovia is also evaluating the broader platform potential of NEV-801 in next-generation oncology applications, including antibody-drug conjugate (ADC) strategies."We selected Creatv Bio because of their strong scientific capabilities and extensive experience supporting biomarker research across
More news about: Creatv MicroTech, Inc.
Jun 01, 2026, 09:24 ET Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
June 1, 2026 /PRNewswire/ -- Servier today announced promising new Phase 1 clinical data for Emi-Le, an investigational antibody drug conjugate (ADC) directed against B7-H4, during an oral session at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago, Illinois.
More news about: Servier Pharmaceuticals
Jun 01, 2026, 08:31 ET The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
several late-stage ADC candidates are advancing through pivotal studies, including izalontamab brengitecan from Bristol Myers Squibb, telisotuzumab adizutecan from AbbVie, and sacituzumab tirumotecan from Merck. These programs highlight the growing industry focus on ADC innovation within
More news about: DelveInsight Business Research, LLP
Jun 01, 2026, 03:23 ET Godawan Artisanal Single Malt Celebrates 125 Global Awards, Taking Rajasthan's Story of Craft and Conservation to the World
environments today stands as a globally recognised Indian single malt. Across prestigious international platforms, including Monde Selection, Clio Awards, ADC Awards, One Club, Spikes Asia, and the International Taste Institute, Godawan has been honored for its liquid, packaging, illustration, design,
More news about: Diageo India
Jun 01, 2026, 01:51 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity.Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show PromiseIn the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of
More news about: Hengrui Pharma
Jun 01, 2026, 00:00 ET Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
Phase III trials for thyroid eye disease; a novel PD-1/VEGF bispecific antibody in Phase 2 trials, being evaluated in combination with a TROP2 ADC; and a B7-H3 ADC in Phase 3 trial for 2L SCLC —both ADCs with strong best-in-class potential.Forward-Looking StatementsThis press release
More news about: Minghui Pharmaceutical
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
immunotherapy: 13.9% in the treatment group vs 19.2% in the control group; proportions receiving targeted therapy: 12.4% vs 17.3%; proportions receiving ADC therapy: 4.5% vs 5.6%; proportions participating in other clinical trials: 0.8% vs 2.3%.Favorable safety profile comparable to tislelizumab
More news about: Akeso, Inc.
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-Biotech
May 30, 2026, 20:00 ET 榮登《柳葉刀》主刊！蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療 PD-L1 陽性 NSCLC III期重磅結果發表
HR值分別為0.28和0.44；同時已觀察到總生存期(OS)的積極獲益趨勢，HR為0.55。蘆康沙妥珠單抗(sac-TMT)聯合組整體安全性可控，聯合治療與蘆康沙妥珠單抗(sac-TMT)單藥或帕博利珠單抗單藥已建立的安全性特征一致，未發現新的安全性信號。這是首個ADC聯合免疫檢查點抑制劑在NSCLC一線治療中達到主要終點的III期臨床研究，首次證明了「ADC+IO」方案(sac-TMT聯合帕博利珠單抗)作為NSCLC一線治療具有實現生存獲益的潛力。該成果問鼎《柳葉刀》主刊，表明這一療法的臨床價值與學術價值已獲得國際權威認可。關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊®)作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主知識產權的新型TROP2
More news about: 科倫博泰
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with
More news about: Whitehawk Therapeutics, Inc.
May 30, 2026, 00:30 ET 2026 ASCO | 蘆康沙妥珠單抗(sac-TMT) III期OptiTROP-Lung05研究成果於ASCO口頭報告和《柳葉刀》同步發佈
全國牽頭主要研究者、同濟大學附屬東方醫院周彩存教授表示：「OptiTROP-Lung05研究取得的積極結果令人振奮。不僅為蘆康沙妥珠單抗在肺癌治療中的『應用前移』提供了循證證據，更率先驗證了『ADC+IO』協同策略在PD-L1陽性晚期NSCLC一線治療中的可行性，有望為廣大肺癌患者帶來全新的生存希望。」
More news about: 科倫博泰
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
May 29, 2026, 23:29 ET Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
May 28, 2026, 16:05 ET Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York
More news about: Whitehawk Therapeutics, Inc.
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator's choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1
More news about: Florida Cancer Specialists & Research Institute
May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform) and ImBiTDC (TDC Platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of
More news about: Nanjing Leads Biolabs Co., Ltd.
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
May 27, 2026, 18:18 ET U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting- DECNUPAZ marks AbbVie's first ADC approved for blood cancerNORTH
More news about: AbbVie
May 27, 2026, 16:31 ET Jetperch Introduces Joulescope JS320 Precision Energy Analyzer for Low-Power Embedded System Development
requirements.The JS320 introduces improved offset stability, reduced leakage current, Enwavify™ v2 technology for current range changes, a 24-bit ADC, wider internal digital processing, and a linear-phase analog path. These improvements are especially important for BLE devices, battery-powered IoT
More news about: Jetperch LLC
May 27, 2026, 09:19 ET GBI Biomanufacturing Appoints Chandra Kelley as Chief Business Officer
McCool, President of GBI Biomanufacturing. "Chandra brings the client and market insights needed to deepen the way we support our early-stage antibody and ADC projects. Her experience structuring integrated and phase-appropriate work packages for rapid early phase supply aligns exceptionally well with GBI's
More news about: GBI Biomanufacturing
May 27, 2026, 05:38 ET Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List
efficient treatment option for adult patients with NF1-PN.Furthermore, Henlius' HLX43, a potential best-in-class broad-spectrum anti-tumor PD-L1 ADC, will have its key subgroup progression-free survival (PFS) data in non-small cell lung cancer (NSCLC) presented for the first time in a Rapid Oral Presentation
More news about: Fosun
May 27, 2026, 05:27 ET 復星國際入選2026《財富》「最受讚賞中國公司榜單」
Series）成份股。多項國際評級與指數表現持續提升，體現了復星在ESG治理、信息披露、風險管理及可持續發展實踐方面的長期積累與穩健成效。復星堅持創新驅動與社會責任相融合，走出一條科創驅動責任引領的可持續發展之路。旗下健康產業秉承為更多患者帶來治癒希望的初心，圍繞臨床空白需求，深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域，積極拓展慢病及罕見病等領域，打造具有長期競爭力的產品管線與綜合解決方案。同時，持續夯實抗體、ADC、小分子、細胞治療等核心技術平台，並拓展核藥、小核酸等前沿技術。在罕見病領域，以復邁寧為例，2025年，由復星醫藥自主研發的1類新藥蘆沃美替尼片（復邁寧）於中國境內獲批兩項
More news about: 復星
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
Phase I, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody-drug conjugate (ADC) in patients with advanced solid tumors.
More news about: Hackensack Meridian John Theurer Cancer Center